Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature | Haematologica
Scaffolds of Bosutinib, Dasatinib, amd Saracatinib, and their respective status in clinical trials.
A trial looking at imatinib and dasatinib for newly diagnosed chronic myeloid leukaemia (SPIRIT 2) | Cancer Research UK
Efficacy of dasatinib and nilotinib in patients with CP CML harboring... | Download Table
Antidiabetic Effects of the Senolytic Agent Dasatinib - Mayo Clinic Proceedings
Dasatinib (BMS-354825) | ≥99%(HPLC) | Selleck | Src inhibitor
Full article: Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States
Fisetin, Quercetin & Dasatinib in Clinical Trials | Dr. James Kirkland Interview Series Ep 4 - YouTube
Dasatinib for Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clinical Trial | Power
Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis - Clinical Therapeutics
Dasatinib (Sprycel) - Oncology Nurse Advisor
Dasatinib - Tyrosine Kinase Inhibitor for Chronic Myeloid Leukaemia (CML) - Clinical Trials Arena
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial - The Lancet Haematology
![PDF] Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/40a02cde3eb975357a6d12781298237c9dc12611/2-Figure1-1.png "PDF] Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia | Semantic Scholar")
PDF] Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia | Semantic Scholar
PDF) Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
Dasatinib (Sprycel) - Oncology Nurse Advisor
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study | Leukemia
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia | NEJM
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial - The Lancet Haematology
The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia - Clinical Therapeutics
Dasatinib - Tyrosine Kinase Inhibitor for Chronic Myeloid Leukaemia (CML) - Clinical Trials Arena
FDA Approves Dasatinib for Some Children with CML - NCI
JPM | Free Full-Text | Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer | HTML
Dasatinib + Quercetin for Alzheimer Disease Clinical Trial | Power
